APA (7th ed.) Citation

MM, H., NA, A., DE, A., RSY, J., EG, A., MA, A., . . . M, M. (2026). Targeting metabolic dysfunction in amyotrophic lateral sclerosis: Therapeutic potential of GLP-1 receptor agonists. Amyotrophic lateral sclerosis & frontotemporal degeneration, 27(5-6), 513. https://doi.org/10.1080/21678421.2026.2627901

Chicago Style (17th ed.) Citation

MM, Helal, Almosilhy NA, Abo-Elnour DE, Jaffal RSY, Allam EG, Almosilhy MA, Batarseh SF, and Meshref M. "Targeting Metabolic Dysfunction in Amyotrophic Lateral Sclerosis: Therapeutic Potential of GLP-1 Receptor Agonists." Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 27, no. 5-6 (2026): 513. https://doi.org/10.1080/21678421.2026.2627901.

MLA (9th ed.) Citation

MM, Helal, et al. "Targeting Metabolic Dysfunction in Amyotrophic Lateral Sclerosis: Therapeutic Potential of GLP-1 Receptor Agonists." Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, vol. 27, no. 5-6, 2026, p. 513, https://doi.org/10.1080/21678421.2026.2627901.